Roche Holding AG (RHHBY) said Tuesday RiskMetrics recommends Genentech Inc. (DNA) shareholders accept the Swiss drug company's $95-a-share takeover offer.

The $46.8 billion purchase for the 44% of Genentech Inc. (DNA) Roche doesn't already own was ultimately reached through a friendly deal two weeks ago after a nearly eight-month battle.

RiskMetrics provides proxy voting recommendations and other shareholder services.

Company Web site: www.roche.com

-By Katharina Bart, Dow Jones Newswires; +41 43 443 8043; katharina.bart@dowjones.com